more_reports

Streetwise Reports' Article Archives — Current Month (5)

Healthcare AI Company Achieves Key Milestones and Secures New Partnerships (07/11/2024)

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects.

more>

Biopharma Co. Reports Strong FQ224 Results Driven (07/11/2024)

Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX).

more>

Texas Biotech Announces Plans for Preclinical Obesity Studies (07/08/2024)

Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note.

more>

AI Health Stock Heading Higher Expert Says (07/02/2024)

Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher.

more>

New Patents and Strategic Partnerships Boost Smart Home Innovation (07/01/2024)

SKYX Platforms Corp. (SKYX:NASDAQ), a leader in smart platform technology, has announced the issuance of six additional patents in the U.S. and internationally, expanding its already robust patent portfolio to over 94 issued and pending patents globally. Find out how these partnerships affect upcoming projects and plans.

more>

More Archives

2024Jun May Apr Mar Feb Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes